Mylan’s price hike for its EpiPen allergy medication is just the latest example of health care costs pressuring consumers, Consumers Union’s Lynn Quincy told AHCJ members in a recent webcast.
Quincy, who leads the consumer-advocacy group’s Healthcare Value Hub and has backed efforts to curb rising drug prices, pointed to other recent price increases such as those by drugmakers Valeant and Turing as symptoms of a massive “market failure.” Continue reading
Several stories about access to public information have caught my eye in the past week. Whether it involves public health data from Florida, evidence in a federal criminal case or embargoes and favored access at a federal agency, it’s clear that journalists are facing obstacles in ensuring the public’s access to information.
In Rhode Island, a judge ruled in favor of a journalist seeking evidence presented in the trial of a doctor now “serving four life sentences for his role in operating a pain management clinic like a ‘pill mill.'” The U.S. Drug Enforcement Administration had refused to release the records since journalist Phil Eil requested them after the trial ended in 2011. Continue reading
High deductibles and out of pocket costs – which are increasing in both Affordable Care Act exchange plans and employer-sponsored coverage – have given new urgency to helping patients (or “consumers” as they’re called nowadays) learn about the cost and quality of care.
If you know both cost and quality, you know more about the value of care. (Assuming the treatment actually is the right and necessary course of care, but that’s a whole other conversation.)
Many programs and experiments are underway to figure out which tools are helpful to patients, how patients are using them, and what are their impact on health spending and utilization. The findings so far can perhaps be summed up as “meh.” Continue reading
Mylan’s price hike for its EpiPen allergy medication fueled an Internet storm this week, with consumers and U.S. legislators expressing outrage over its decision to raise the price about 400% since 2007 to as much as $500 or more. The backlash appeared tied in part to timing as U.S. children head back to school, with parents of those needing EpiPens to treat allergic reactions coming to grips with the hefty price tag.
The incident brought echoes of another drug price hike – the 2015 increase by Turing Pharmaceutical’s malaria and HIV medicine Darapim, another move that brought scrutiny by the House Oversight and Government Reform Committee of the company’s chief executive officer. Continue reading
Source: Report Card on State Price Transparency Laws — July 2016Here’s how price transparency should work for a woman with a silver-level insurance plan in one state. Assume this consumer could go to any hospital and would choose based on the cost of care, meaning her out-of-pocket costs (deductible plus co-insurance). She could pay $5,079 at the highest-priced facility or $3,531 at the lowest-priced hospital. The difference between the two is $1,548.
Progress toward widespread price transparency comes slowly, according to the latest annual report from the Health Care Incentives Improvement Institute (HCI3) and the Catalyst for Payment Reform (CPR). In the “Report Card on State Price Transparency Laws – July 2016,” issued on Tuesday, the authors, Suzanne Delbanco, CPR’s executive director, and François de Brantes, HCI3’s executive director, explained what states are doing to give consumers the information they need to shop for care based on price.
As in past years, most states are doing poorly: 43 states earned an F grade for failing to meet even minimum standards. Last year, 45 states got an F. Continue reading